Market Place
Sourcing Support
BridgeBio Launches GondolaBio With $300M, Transfers Programs to Joint Venture
22 Aug 2024 //
BIOSPACE
Bridge Biotherapeutics And HitGen Partner On Cancer Therapeutics
22 Aug 2024 //
PR NEWSWIRE
Bridge Biotherapeutics Completes Enrollment For BBT-877 IPF Phase 2a Study
29 Jul 2024 //
PR NEWSWIRE
Bridge Collaboration with University to Explore Combination Therapy of BBT-877
28 Mar 2024 //
PR NEWSWIRE
Bridge Announces Collaboration with University of Colorado to Explore BBT-877
26 Mar 2024 //
PR NEWSWIRE
GPCR Therapeutics Announces Out-Licensing Agreement with Bridge Biotherapeutics
14 Dec 2023 //
GLOBENEWSWIRE
Bridge Announces Initiation of Phase 1/2 Trial of BBT-207 in EGFR-Mutant NSCLC
30 Oct 2023 //
PR NEWSWIRE
Bridge Announces Positive Recommendation from Data Committee of the BBT-877
25 Oct 2023 //
PR NEWSWIRE
Bridge Releases Updated Preclinical Data for BBT-207 at the AACR Meeting
18 Apr 2023 //
PR NEWSWIRE
Bridge Announces First Patient Dosed in its Phase 2a Clinical Trial of BBT-877
12 Apr 2023 //
PR NEWSWIRE
Bridge to Present Data of BBT-207 at the AACR 2023 Annual Meeting
15 Mar 2023 //
PR NEWSWIRE
Bridge Biotherapeutics` ulcerative colitis drug fails Phase II trial
21 Feb 2023 //
ENDPTS
Bridge holds firm after midphase flop in ulcerative colitis
21 Feb 2023 //
FIERCE BIOTECH
Bridge Biotherapeutics Presents Phase 2a Clinical Trial Results For BBT-401
20 Feb 2023 //
PR NEWSWIRE
Bridge Biotherapeutics Initiates Phase 2 Clinical Trial of BBT-877
07 Nov 2022 //
BIOSPACE
Brainomix and Bridge Biotherapeutics, Inc. Announce Partnership
07 Sep 2022 //
PRNEWSWIRE
Brainomix and Bridge Biotherapeutics enter artificial intelligence partnership
07 Sep 2022 //
PHARMATIMES
Bridge Biotherapeutics, Brainomix team up for P2 idiopathic pulmonary fibrosis
05 Sep 2022 //
KOREABIOMED
Bridge Presented Non-clinical Study Results for 2 IPF Candidates a
01 Sep 2022 //
PRNEWSWIRE
Bridge Bio Presents Promising Interim Study Results from PI Study of BBT-176
09 Aug 2022 //
PRNEWSWIRE
Bridge Bio to Present Interim Clinical Data from Ongoing PI Study of BBT-176
12 Jul 2022 //
PRNEWSWIRE
Bridge Bio to Present Comprehensive Pipeline Updates at the 2022 BIO
26 May 2022 //
ASIAONE
Bridge Bio to Announce Updated Data from its Phase 1 Study of BBT-176
10 May 2022 //
PRNEWSWIRE
Bridge Bio Presented Preclinical Data of BBT-207 at the AACR
12 Apr 2022 //
PRNEWSWIRE
Bridge Bio to Present Preclinical Data of BBT-207 at AACR 2022
09 Mar 2022 //
PRNEWSWIRE
Korea reinforces strategic focus on fibrotic diseases
08 Mar 2022 //
BIOSPECTRUMASIA
Bridge Bio, Scripps Research Collaborate to Develop Discovery Platform
07 Feb 2022 //
PRNEWSWIRE
Bridge Announces Initiation of the PhI Clinical Trial for BBT-401
19 Oct 2021 //
PRNEWSWIRE
Bridge Biotherapeutics Integrates CDD Vault Collaborative Database Solution
26 Jun 2021 //
PR NEWSWIRE
Bridgebio Announces the Initiation of Patient Dosing in Study for BBT-401
14 Jun 2021 //
PRNEWSWIRE
Bridge Biotherapeutics Announces the Initiation of Patient Dosing for BBT-401
14 Jun 2021 //
PRNEWSWIRE
Bridge Biotherapeutics begins phase 1/2 trial of BBT-176 in EGFR-mutant NSCLC
08 Apr 2021 //
PHARMABIZ
Bridge Announces Initiation of Phase 1/2 Clinical Trial of BBT-176
07 Apr 2021 //
PRNASIA
Bridge Biotherapeutics starts clinical trial of BBT-176 for lung cancer
07 Apr 2021 //
CLINICALTRIALSARENA
Bridge Announces Initiation of Phase 1/2 Clinical Trial of BBT-176
06 Apr 2021 //
PRNEWSWIRE
Bridge Announces Initiation of Phase 1/2 Clinical Trial of BBT-176
06 Apr 2021 //
PRNASIA
Bridge announces safety and efficacy profiles of phase 2a trial of BBT-401
24 Sep 2020 //
PHARMABIZ
Bridge Biotherapeutics Announces Detailed Plans for the PhIIa Study of BBT-401
22 Sep 2020 //
PRNEWSWIRE
Bridge Biotherapeutics becomes BaseLaunch`s first Asia Pacific partner
15 Jul 2020 //
PRNASIA
Bridge Biotherapeutics Announces IND Clearance of BBT-176, EGFR TKI for NSCLC
07 May 2020 //
PRNEWSWIRE
Bridge`s Discloses Interim Results from the First Cohort of Ph 2a of BBT-401
08 Apr 2020 //
PRNEWSWIRE
Atomwise, Bridge Biotherapeutics pen $1B deal for AI-devised molecules
10 Mar 2020 //
FIERCE BIOTECH
Bridge Biotherapeutics Enters AI-based Research Collaboration with Atomwise
09 Mar 2020 //
BUSINESS WIRE
Atomwise and Bridge Biotherapeutics Sign $1B Deal
09 Mar 2020 //
BUSINESS WIRE
Bridge Biotherapeutics acquires new candidate for back-eye diseases
06 Feb 2020 //
BIOSPECTRUMASIA
Bridge Biotherapeutics Acquires a New Drug Development Candidate
05 Feb 2020 //
PR NEWSWIRE
Bridge Biotherapeutics Announces FDA IND Clearance for BBT-176
20 Jan 2020 //
PR NEWS WIRE
Bridge Therapeutics to seek US FDA approval for opioid dependence drug, BT-219
09 Nov 2019 //
PHARMABIZ
Boehringer enlists another virtual biotech for its foray into retinal diseases
20 Sep 2019 //
ENDPTS
Boehringer Ingelheim`s Ofev wins FDA approval for use in scleroderma patients
10 Sep 2019 //
ENDPOINTSNEWS
Boehringer Ingelheim, Bridge Biotherapeutics to Collaborate on IPF Pipeline
23 Jul 2019 //
CONTRACT PHARMA
Boehringer expands IPF pipeline with addition of BBT-877
19 Jul 2019 //
PHARMATIMES
Boehringer picks up Bridge Biotherapeutics` IPF med for $50M
19 Jul 2019 //
FIERCE BIOTECH
Boehringer Ingelheim Gambles $2.62 Billion on Two Fibrotic Disease Deals
19 Jul 2019 //
BIOSPACE
Bridge`s Announces Data Presentation from First-in-Human Study of BBT-877
21 May 2019 //
PRNASIA
